The primary objective of this study is to conduct a proof of concept pilot study that will
provide a preliminary evaluation of the safety of plerixafor alone or in combination with
bortezomib on plasma cell mobilization, Human Leukocyte Antigen (HLA) antibody levels and
toxicity profile in sensitized patients awaiting kidney transplantation.
The secondary objective of this study is to conduct additional analyses of the study regimen
on HLA antibody levels using multiple different assays and statistical analysis.